{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-068992","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.954814+00:00","generated_at":"2026-06-22T11:06:13.712529+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Nektar Therapeutics Q3 2022 net loss narrows to $59M; cash at $546M, runway through mid-2025","bullets":["Cash and investments at $546.4M at Sep 30, down from $628.2M at Q2 end; cash runway through mid-2025.","Net loss Q3 $59.0M ($0.31 per share) vs $129.7M ($0.70) year ago; revenue $23.6M (non-cash royalty).","R&D expense fell to $33.6M from $103.7M due to wind-down of bempegaldesleukin program.","Restructuring/impairment costs $124.3M year-to-date, including $58.5M non-cash lease/equipment impairment.","Pipeline: NKTR-358 (w/ Lilly) proof-of-concept in atopic dermatitis; NKTR-255 Phase 2 in large B-cell lymphoma planned."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-068992","json":"https://secwatch.observer/filing/0001213900-22-068992.json","markdown":"https://secwatch.observer/filing/0001213900-22-068992.md","text":"https://secwatch.observer/filing/0001213900-22-068992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/0001213900-22-068992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/ea167983-8k_nektarther.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T11:06:13.712529+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a5bea22fde5e0926dfe8a0275fb714825e1e05b3","claim":"NEKTAR THERAPEUTICS reported third quarter ended September 30, 2022 results: revenue $23.6 million, net income $59.0 million, EPS $0.31 basic and diluted loss per share.","evidence_excerpt":"lay the foundation for continued pipeline progress.” Summary of Financial Results Revenue, which primarily includes non-cash royalty revenue, in the third quarter of 2022 was $23.6 million as compared to $24.9 million in the third quarter of 2021. Revenue for the first nine months of 2022 was $70.0 million as compared to $76.9 million in the first nine months of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390022068992/0001213900-22-068992-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$23.6 million"},{"label":"Net income","value":"$59.0 million"},{"label":"EPS","value":"$0.31 basic and diluted loss per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}